Nasal Spray Delivers Appetite-Stimulating Peptide to Mouse Brain
Background
The ghrelin signaling system plays a crucial role in regulating appetite, metabolism, and reward pathways. While ghrelin mimetics hold therapeutic potential for conditions like anorexia or cachexia (muscle wasting), their systemic administration often leads to rapid degradation and poor brain penetration due to the blood-brain barrier. This study addresses the knowledge gap of whether intranasal delivery can effectively bypass these barriers to engage the brain's ghrelin signaling system in a non-invasive manner.
Results
Intranasal Ghr-MIM demonstrated significant and rapid brain uptake, with peak concentrations observed in the hypothalamus within 30 minutes. Compared to controls, treated mice showed a 2.8-fold increase in GHSR-1a receptor occupancy in the arcuate nucleus and paraventricular nucleus (p<0.001). Furthermore, there was a 45% increase in c-Fos positive neurons in the arcuate nucleus (p<0.01), indicating enhanced neuronal activation. Gene expression analysis revealed a 2.1-fold upregulation of NPY (neuropeptide Y) and AgRP (agouti-related peptide) mRNA in the hypothalamus (p<0.05), both known to stimulate appetite. Intranasal Ghr-MIM significantly increased cumulative food intake by 38% compared to saline-treated controls over the first 24 hours post-administration (p<0.001), with a sustained effect observed for up to 48 hours. This effect was dose-dependent, with 0.5 mg/kg showing optimal efficacy.
Why It Matters
This study provides compelling evidence that intranasal delivery is a viable and effective route for engaging the brain's ghrelin signaling system. This non-invasive approach could circumvent the challenges of systemic administration, offering a novel therapeutic strategy. Such a delivery method could pave the way for new treatments for conditions characterized by appetite loss, such as cancer cachexia, anorexia nervosa, or age-related sarcopenia. Future research should focus on optimizing formulations, conducting chronic toxicity studies, and eventually progressing to human clinical trials (Phase I and II) to evaluate safety and efficacy in patients.